Pliant Therapeutics reported second quarter 2026 financial results with a net loss of $22.4 million, compared to $43.3 million in the prior-year period. Research and development expenses decreased to $16.7 million from $32.2 million due to the termination of the bexotegrast IPF program and reduced headcount. General and administrative expenses fell to $7.1 million from $13.4 million, also driven by lower personnel costs. The company ended the quarter with $159.6 million in cash, cash equivalents, and short-term investments, sufficient to fund operations into late 2028. Clinically, enrollment in the FORTIFY Phase 1b trial for PLN-101095 remains strong and ahead of schedule, with interim data expected in 2027. The board appointed Flavia Borellini and Robert Iannone to enhance oncology expertise. Pliant Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics.

On July 9, 2026, Pliant Therapeutics increased its Board of Directors size from seven to nine members. The company appointed Robert Iannone, M.D., M.S.C.E. as a Class I director and Flavia Borellini, Ph.D. as a Class II director. Dr. Borellini was named chairperson of the Research and Development (R&D) Committee, and Dr. Iannone was appointed as a member of the same committee. Both directors will receive an annual retainer of $40,000, with additional R&D Committee retainers of $15,000 for Dr. Borellini and $7,500 for Dr. Iannone. Each new director was granted options to purchase 60,000 shares of common stock vesting over three years. Pliant Therapeutics is a biotechnology company that develops therapeutic treatments.